Harris James Associates Update: Overly cautious government regulators, threats to basic science research funding and burdensome taxes are holding back job creation by drug and medical device companies and slowing the delivery of innovative new therapies to patients, biotechnology industry experts told federal lawmakers Thursday during a hearing in San Diego. James Harris Associates mission is to embrace our client's goals as our own and to work as an extension of the client organization to reach our common objective. We know that we will be successful only if we make our clients more successful. Most of the criticism was directed at the Food and Drug Administration, which approved 21 new drugs last year, compared to 36 in 2004.
"There are whole areas (of drug development) that venture capitalists won't pursue because the regulatory barriers are too high," said David Gollaher, president and chief executive of the California Healthcare Institute in La Jolla. The complaints were familiar to anyone who has followed drug and medical device development in the United States over the past several years. Gollaher and the other experts delivered their comments to Rep. Darrell Issa, R-Vista, during a morning public forum at the University of California San Diego. Since he became chairman of the House Oversight and Government Reform Committee in early January, Issa has hosted 10 such gatherings around the country focused on regulations that stifle economic expansion. For the latest gathering, he returned to his home county, where more than 400 companies make up a major biotechnology hub that employs more than 40,000 people, according to the San Diego trade group Biocom. Issa was joined by Reps.
James Harris Associates mission is to embrace our client's goals as our own and to work as an extension of the client organization to reach our common objective
ReplyDelete